241 related articles for article (PubMed ID: 9524096)
1. High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma.
Chang SM; Barker FG; Huhn SL; Nicholas MK; Page M; Rabbitt J; Prados MD
J Neurooncol; 1998 Apr; 37(2):169-76. PubMed ID: 9524096
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.
Odia Y; Kreisl TN; Aregawi D; Innis EK; Fine HA
J Neurooncol; 2015 Oct; 125(1):191-5. PubMed ID: 26285768
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon alpha-2a as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomised multicentre trial.
Chiesa MD; Passalacqua R; Michiara M; Franciosi V; Di Costanzo F; Bisagni G; Camisa R; Buti S; Tomasello G; Cocconi G;
Acta Biomed; 2007 Dec; 78(3):204-9. PubMed ID: 18330080
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.
Tang P; Roldan G; Brasher PM; Fulton D; Roa W; Murtha A; Cairncross JG; Forsyth PA
J Neurooncol; 2006 Jul; 78(3):311-6. PubMed ID: 16710748
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma.
Buckner JC; Brown LD; Kugler JW; Cascino TL; Krook JE; Mailliard JA; Kardinal CG; Tschetter LK; O'Fallon JR; Scheithauer BW
J Neurosurg; 1995 Mar; 82(3):430-5. PubMed ID: 7861221
[TBL] [Abstract][Full Text] [Related]
6. Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.
Rajkumar SV; Buckner JC; Schomberg PJ; Cascino TL; Burch PA; Dinapoli RP
Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):297-302. PubMed ID: 9457812
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas.
Brandes AA; Scelzi E; Zampieri P; Rigon A; Rotilio A; Amista P; Berti F; Fiorentino MV
Am J Clin Oncol; 1997 Aug; 20(4):364-7. PubMed ID: 9256890
[TBL] [Abstract][Full Text] [Related]
8. Interferon alpha-2a and external beam radiotherapy in the initial management of patients with glioma: a pilot study of the National Biotherapy Study Group.
Dillman RO; Wiemann M; Oldham RK; Soori G; Bury M; Hafer R; Church C; DePriest C
Cancer Biother; 1995; 10(4):265-71. PubMed ID: 8590891
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood.
Pollack IF; DaRosso RC; Robertson PL; Jakacki RL; Mirro JR; Blatt J; Nicholson S; Packer RJ; Allen JC; Cisneros A; Jordan VC
Clin Cancer Res; 1997 Jul; 3(7):1109-15. PubMed ID: 9815790
[TBL] [Abstract][Full Text] [Related]
10. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study.
Hercbergs AA; Goyal LK; Suh JH; Lee S; Reddy CA; Cohen BH; Stevens GH; Reddy SK; Peereboom DM; Elson PJ; Gupta MK; Barnett GH
Anticancer Res; 2003; 23(1B):617-26. PubMed ID: 12680157
[TBL] [Abstract][Full Text] [Related]
11. Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy.
Preul MC; Caramanos Z; Villemure JG; Shenouda G; LeBlanc R; Langleben A; Arnold DL
Neurosurgery; 2000 Feb; 46(2):306-18. PubMed ID: 10690719
[TBL] [Abstract][Full Text] [Related]
12. Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma.
Dillman RO; Shea WM; Tai DF; Mahdavi K; Barth NM; Kharkar BR; Poor MM; Church CK; DePriest C
Neuro Oncol; 2001 Jan; 3(1):35-41. PubMed ID: 11305415
[TBL] [Abstract][Full Text] [Related]
13. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
14. Treatment of recurrent malignant gliomas with chronic oral high-dose tamoxifen.
Couldwell WT; Hinton DR; Surnock AA; DeGiorgio CM; Weiner LP; Apuzzo ML; Masri L; Law RE; Weiss MH
Clin Cancer Res; 1996 Apr; 2(4):619-22. PubMed ID: 9816211
[TBL] [Abstract][Full Text] [Related]
15. Biological activity of all-trans-retinoic acid with and without tamoxifen and alpha-interferon 2a in breast cancer patients.
Toma S; Raffo P; Nicolo G; Canavese G; Margallo E; Vecchio C; Dastoli G; Iacona I; Regazzi-Bonora M
Int J Oncol; 2000 Nov; 17(5):991-1000. PubMed ID: 11029503
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
[TBL] [Abstract][Full Text] [Related]
17. Short communication: phase I clinical and gene modulatory evaluation of tamoxifen and IFN-alpha2b.
Thakkar SG; Peereboom D; Olencki T; Jacobs B; Elson P; Rybicki L; Lindner DJ; Borden EC
J Interferon Cytokine Res; 2006 Nov; 26(11):800-3. PubMed ID: 17115898
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
Lu YS; Hsu C; Li CC; Kuo SH; Yeh KH; Yang CH; Hsu CH; Wu CY; Cheng AL
Hepatogastroenterology; 2004; 51(57):815-9. PubMed ID: 15143923
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma.
Gause BL; Sharfman WH; Janik JE; Curti BD; Steis RG; Urba WJ; Smith JW; Alvord WG; Longo DL
Cancer Invest; 1998; 16(6):374-80. PubMed ID: 9679527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
